Literature DB >> 18079970

The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice.

Yuri Kim1, Dillon Phan, Eva van Rooij, Da-Zhi Wang, John McAnally, Xiaoxia Qi, James A Richardson, Joseph A Hill, Rhonda Bassel-Duby, Eric N Olson.   

Abstract

The adult heart responds to excessive neurohumoral signaling and workload by a pathological growth response characterized by hypertrophy of cardiomyocytes and activation of a fetal program of cardiac gene expression. These responses culminate in diminished pump function, ventricular dilatation, wall thinning, and fibrosis, and can result in sudden death. Myocyte enhancer factor-2 (MEF2) transcription factors serve as targets of the signaling pathways that drive pathological cardiac remodeling, but the requirement for MEF2 factors in the progression of heart disease in vivo has not been determined. MEF2A and MEF2D are the primary MEF2 factors expressed in the adult heart. To specifically determine the role of MEF2D in pathological cardiac remodeling, we generated mice with a conditional MEF2D allele. MEF2D-null mice were viable, but were resistant to cardiac hypertrophy, fetal gene activation, and fibrosis in response to pressure overload and beta-chronic adrenergic stimulation. Furthermore, we show in a transgenic mouse model that forced overexpression of MEF2D was sufficient to drive the fetal gene program and pathological remodeling of the heart. These results reveal a unique and important function for MEF2D in stress-dependent cardiac growth and reprogramming of gene expression in the adult heart.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18079970      PMCID: PMC2129240          DOI: 10.1172/JCI33255

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP.

Authors:  C I Rodríguez; F Buchholz; J Galloway; R Sequerra; J Kasper; R Ayala; A F Stewart; S M Dymecki
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

2.  Epiblast-restricted Cre expression in MORE mice: a tool to distinguish embryonic vs. extra-embryonic gene function.

Authors:  M D Tallquist; P Soriano
Journal:  Genesis       Date:  2000-02       Impact factor: 2.487

3.  Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway.

Authors:  H Wu; B Rothermel; S Kanatous; P Rosenberg; F J Naya; J M Shelton; K A Hutcheson; J M DiMaio; E N Olson; R Bassel-Duby; R S Williams
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

4.  The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo.

Authors:  Q Liang; L J De Windt; S A Witt; T R Kimball; B E Markham; J D Molkentin
Journal:  J Biol Chem       Date:  2001-05-16       Impact factor: 5.157

5.  Cardiac hypertrophy is not a required compensatory response to short-term pressure overload.

Authors:  J A Hill; M Karimi; W Kutschke; R L Davisson; K Zimmerman; Z Wang; R E Kerber; R M Weiss
Journal:  Circulation       Date:  2000-06-20       Impact factor: 29.690

6.  Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor.

Authors:  Francisco J Naya; Brian L Black; Hai Wu; Rhonda Bassel-Duby; James A Richardson; Joseph A Hill; Eric N Olson
Journal:  Nat Med       Date:  2002-10-15       Impact factor: 53.440

7.  CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo.

Authors:  R Passier; H Zeng; N Frey; F J Naya; R L Nicol; T A McKinsey; P Overbeek; J A Richardson; S R Grant; E N Olson
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

8.  Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation.

Authors:  T A McKinsey; C L Zhang; J Lu; E N Olson
Journal:  Nature       Date:  2000-11-02       Impact factor: 49.962

9.  Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy.

Authors:  Chun Li Zhang; Timothy A McKinsey; Shurong Chang; Christopher L Antos; Joseph A Hill; Eric N Olson
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

10.  Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma.

Authors:  Xueli Bai; Lihua Wu; Tingbo Liang; Zhiqiang Liu; Junjian Li; Donglin Li; Haiyang Xie; Shengyong Yin; Jun Yu; Qi Lin; Shusen Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-05       Impact factor: 4.553

View more
  112 in total

1.  Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.

Authors:  Tetsuo Konno; Dan Chen; Libin Wang; Hiroko Wakimoto; Polakit Teekakirikul; Matthew Nayor; Masataka Kawana; Seda Eminaga; Joshua M Gorham; Kumar Pandya; Oliver Smithies; Francisco J Naya; Eric N Olson; J G Seidman; Christine E Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-05       Impact factor: 11.205

2.  Panhistone deacetylase inhibitors inhibit proinflammatory signaling pathways to ameliorate interleukin-18-induced cardiac hypertrophy.

Authors:  Gipsy Majumdar; Robert J Rooney; I Maria Johnson; Rajendra Raghow
Journal:  Physiol Genomics       Date:  2011-09-27       Impact factor: 3.107

3.  MEF2D deficiency in neonatal cardiomyocytes triggers cell cycle re-entry and programmed cell death in vitro.

Authors:  Nelsa L Estrella; Amanda L Clark; Cody A Desjardins; Sarah E Nocco; Francisco J Naya
Journal:  J Biol Chem       Date:  2015-08-20       Impact factor: 5.157

4.  Network-based predictions of in vivo cardiac hypertrophy.

Authors:  Deborah U Frank; Matthew D Sutcliffe; Jeffrey J Saucerman
Journal:  J Mol Cell Cardiol       Date:  2018-07-17       Impact factor: 5.000

5.  The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload.

Authors:  Johannes Backs; Thea Backs; Stefan Neef; Michael M Kreusser; Lorenz H Lehmann; David M Patrick; Chad E Grueter; Xiaoxia Qi; James A Richardson; Joseph A Hill; Hugo A Katus; Rhonda Bassel-Duby; Lars S Maier; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

6.  The scaffold protein muscle A-kinase anchoring protein β orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure.

Authors:  Michael D Kritzer; Jinliang Li; Catherine L Passariello; Marjorie Gayanilo; Hrishikesh Thakur; Joseph Dayan; Kimberly Dodge-Kafka; Michael S Kapiloff
Journal:  Circ Heart Fail       Date:  2014-05-08       Impact factor: 8.790

7.  Steroid receptor coactivator-2 is a dual regulator of cardiac transcription factor function.

Authors:  Erin L Reineke; Ashley Benham; Benjamin Soibam; Erin Stashi; Heinrich Taegtmeyer; Mark L Entman; Robert J Schwartz; Bert W O'Malley
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

8.  Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy.

Authors:  Ding-Sheng Jiang; Zhou-Yan Bian; Yan Zhang; Shu-Min Zhang; Yi Liu; Rui Zhang; Yingjie Chen; Qinglin Yang; Xiao-Dong Zhang; Guo-Chang Fan; Hongliang Li
Journal:  Hypertension       Date:  2013-04-15       Impact factor: 10.190

Review 9.  The rationale for cardiomyocyte resuscitation in myocardial salvage.

Authors:  Gerald W Dorn; Abhinav Diwan
Journal:  J Mol Med (Berl)       Date:  2008-06-19       Impact factor: 4.599

10.  A pathway involving HDAC5, cFLIP and caspases regulates expression of the splicing regulator polypyrimidine tract binding protein in the heart.

Authors:  Junmei Ye; Miriam Llorian; Maria Cardona; Anthony Rongvaux; Rana S Moubarak; Joan X Comella; Rhonda Bassel-Duby; Richard A Flavell; Eric N Olson; Christopher W J Smith; Daniel Sanchis
Journal:  J Cell Sci       Date:  2013-02-19       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.